Open AccessThe role of Gefitinib in patients with non-small-cell lung cancer in India
Author(s) -
Asmita Mehta,
Wesley Jose,
Keechilat Pavithran,
Ganesan S Triavadi
Publication year - 2013
Publication title -
indian journal of palliative care/indian journal of palliative care
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.395
H-Index - 26
eISSN - 1998-3735
pISSN - 0973-1075
DOI - 10.4103/0973-1075.110237
Subject(s) - gefitinib , medicine , lung cancer , oncology , chemotherapy , expanded access , cohort , epidermal growth factor receptor , tyrosine kinase inhibitor , cancer
Gefitinib, an epidermal growth factor receptor-tyrosine kinase inhibitor, represents a new treatment option for patients with advanced non-small-cell lung cancer (NSCLC). We analyzed the data of patients who received Gefitinib for NSCLC in a tertiary care center in South India.